Who is sponsoring NCT05390073?

NCT05390073 is sponsored by Cairo University.

What drugs are being tested in NCT05390073?

Interventions in NCT05390073: growth hormone level and insulin like growth factor 1.

What condition does NCT05390073 study?

NCT05390073 studies Epidermolysis Bullosa Dystrophica.

Is NCT05390073 still recruiting?

NCT05390073 is currently status unknown. Last updated 25 May 2022.

Last reviewed 2022-05-25 · How we verify

NCT05390073

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Growth Hormone in EB

Status unknown Last updated 25 May 2022

What this trial tests

trial testing growth hormone level and insulin like growth factor 1 in Epidermolysis Bullosa Dystrophica in 50 participants. Status unknown.

Timeline

25 May 2022

Primary endpoint
10 June 2022

15 June 2022

Quick facts

Lead sponsor	Cairo University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	25 May 2022
Primary completion	10 June 2022
Estimated completion	15 June 2022

Drugs / interventions tested

growth hormone level and insulin like growth factor 1

Conditions studied

Epidermolysis Bullosa Dystrophica — all drugs for Epidermolysis Bullosa Dystrophica →

Sponsor

Cairo University

Who can join

Adults 1 Month to 12, any sex, with Epidermolysis Bullosa Dystrophica. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Growth is extremely affected in epidermolysis bullosa patients

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Assessment of Growth Hormone and Insulin-Like Growth Factor 1 in Children With Epidermolysis Bullosa Dystrophica.
El Darouti M, Zaki IS, Mousa N, El Sayed H. · · 2025 · PMID 41287410 · DOI 10.1111/pde.70113

Verify or expand the search:

Other recruiting trials for Epidermolysis Bullosa Dystrophica

Currently open trials in the same condition.

NCT06177353 — Study of the Blood and Skin Immunological Profile of Patients With Recessive Dystrophic Epidermolysis Bullosa: in Vivo A · recruiting
NCT05843994 — Artificial Intelligence Patient App for RDEB SCCs · active not recruiting
NCT04171661 — Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa · EARLY_PHASE1 · active not recruiting
NCT01019148 — Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa · recruiting

Other Cairo University trials

Trials by the same sponsor.

NCT04155528 — Effect of Music Therapy on Postoperative Health Outcomes · NA · not yet recruiting
NCT07363239 — CBCT-Based Safety Distance for Implant Placement Near the Inferior Alveolar Canal · not yet recruiting
NCT07374575 — Egyptian Dental Professionals' Perspectives on the Oral Microbiome and Exosomes · not yet recruiting
NCT07381153 — In-Vitro Cytotoxicity Assessment of INOX (Nanoksa G Plus) Polymer Discs · not yet recruiting
NCT07375394 — 3D-Printed Extraoral Camera for Standardized Dental Photography · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05390073 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cairo University
Last refreshed: 25 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05390073.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing